Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repayments
Ratios

Ani Pharmaceuticals (ANIP) Other Gross PP&E Adjustments (2016 - 2026)

Ani Pharmaceuticals' Other Gross PP&E Adjustments history spans 15 years, with the latest figure at $114.5 million for Q4 2025.

  • On a quarterly basis, Other Gross PP&E Adjustments rose 13.85% to $114.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $114.5 million, a 13.85% increase, with the full-year FY2025 number at $114.5 million, up 13.85% from a year prior.
  • Other Gross PP&E Adjustments hit $114.5 million in Q4 2025 for Ani Pharmaceuticals, up from -$20.3 million in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for ANIP hit a ceiling of $114.5 million in Q4 2025 and a floor of -$60.3 million in Q1 2025.
  • Historically, Other Gross PP&E Adjustments has averaged $25.1 million across 5 years, with a median of $36.2 million in 2021.
  • Biggest five-year swings in Other Gross PP&E Adjustments: surged 34.39% in 2022 and later crashed 217.99% in 2024.
  • Tracing ANIP's Other Gross PP&E Adjustments over 5 years: stood at $75.6 million in 2021, then rose by 0.44% to $76.0 million in 2022, then rose by 2.07% to $77.5 million in 2023, then rose by 29.74% to $100.6 million in 2024, then increased by 13.85% to $114.5 million in 2025.
  • Business Quant data shows Other Gross PP&E Adjustments for ANIP at $114.5 million in Q4 2025, -$20.3 million in Q3 2025, and -$40.7 million in Q2 2025.